Harbour BioMed

Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020

Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer MoreLess

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibody therapeutics for oncology and immunology.

The company develops its portfolio and pipeline through internal research and development, collaborations, and acquisitions. Its proprietary antibody technology platforms, Harbour Mice®, generate fully human monoclonal antibodies in two formats: H2L2 and heavy chain only (HCAb). The HCAb-based immune cell engagers (HBICE®) are designed to deliver tumor-killing effects that are not achievable with traditional combination therapies. The integration of Harbour Mice® with a single B cell cloning platform provides an efficient antibody discovery engine for developing next-generation therapeutic antibodies.

Keywords: biopharmaceutical, antibody therapeutics, oncology, immunology, monoclonal antibodies, Harbour Mice, HBICE, H2L2, HCAb, B cell cloning

Valuation $926M

Revenue $202M

EBITDA $95M

Total funding $100–500M

Power Law Thoroughbred$100M+ revenue

Talent graph

Harbour BioMed's talent

Book a demo to see the people

Team profiled 8 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

20 investors on Harbour BioMed's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 13 investors entered at this stage

Legend Capital

Advantech Capital

GIC

Cambridge University Endowment Fund (CUEF)

Vertex Holdings

Sovereign Wealth Funds

China Life Private Equity Investment

Zheshang Venture Capital

SK Group

Efung Capital

Zhejiang University Future Capital

Greater Bay Area Fund

JT New Century

Series B+ 7 investors entered at this stage

Hudson Bay Capital Management

OrbiMed

ShenZhen GTJA Investment Group

Octagon Capital Partners

Sage Partners

Country Garden

AstraZeneca

Global footprint

Where Harbour BioMed has talent and traffic

Workforce by country

5 countries with
team presence

🇨🇳 China76.5%

🇺🇸 United States19.8%

🇭🇰 Hong Kong1.2%

🇳🇱 Netherlands1.2%

🇬🇧 United Kingdom1.2%

5 countries shown

Web traffic by country

4.5K monthly visits
across markets

🇺🇸 United States66.7%

🇮🇳 India15.6%

🇨🇦 Canada13.3%

🇭🇰 Hong Kong4.4%

Top 4 markets shown

Patent intelligence

$48M patent portfolio · 89 active families

Estimated portfolio value

$48M

5.1% of market cap · 6.6× smaller than top peer Pacific Biosciences ($314M)

89 active patent families

Where Harbour BioMed innovates Antigen Binding FragmentBinding proteinAntibodyAntiendomysial antibodiesAntigen

Where Harbour BioMed concentrates vs peers

Each axis is a top-10 topic across Harbour BioMed and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Harbour BioMed

An AI-synthesized read of the highest-engagement posts about Harbour BioMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harbour BioMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles